ORUKA THERAPEUTICS INC (ORKA)
Health Care · biotechnology · NASDAQ
Oruka Therapeutics is a clinical-stage biotech developing engineered monoclonal antibodies to set a new standard of care in chronic skin diseases like psoriasis.
What ORUKA THERAPEUTICS INC does
Oruka Therapeutics is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody therapeutics for chronic skin diseases and inflammatory and immunology indications. The company utilizes antibody engineering and half-life extension technology to target validated mechanisms, aiming to improve efficacy and dosing frequency for conditions such as psoriasis, hidradenitis suppurativa, and psoriatic arthritis.
Themes: inflammatory and immunology (I&I), psoriasis treatment, monoclonal antibodies, dermatology drug development
Fundamentals
- Price$77.28 as of 2026-10-08 close
- Market cap$5.1B as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return+241.7% 2025-10-08 close $22.62 → 2026-10-08 close $77.28
- P/En/a negative earnings
- ROE-22.3% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Beta1.21 as of 2026-09-02
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How ORKA compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ORUKA THERAPEUTICS INC looks technically
ORUKA THERAPEUTICS INC (ORKA) is trading 21.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 269 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 25, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 29, in oversold territory (below 30). It just made a new 20-day low, its first since 2026-06-18, breaking below its recent trading range. It is 33.1% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 21.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +21.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $94.97 | $94.97 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $63.51 | $63.51 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 20 calendar days ago — the swings before that are what the structure reading is measured on | 20 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 98.29. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 269 trading days ago — a "golden cross", a bullish long-term signal | 269 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 25, with sellers in control | 25.3 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 29, in oversold territory (below 30) | 28.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($75.83 to $96.78) — its "stochastic" reading is 7 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 6.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $115.51 | $115.51 |
|---|---|---|
| From the 52-week high | it is 33.1% below its 52-week high (its highest price of the past year) | -33.1% |
| Above the 52-week low | it is 419.0% above its 52-week low (its lowest price of the past year) | +419.0% |
| Below the 52-week high | it is 33.1% below its highest point of the past year | 33.1% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-06-18, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, its first since 2026-06-18, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $75932640.00 (set on 2000-02-18) | $75932640.00 |
| Given back of the 52-week move | over the past year its closes ranged ($15.05 to $113.08), and it has given back roughly a third of its rise from last year’s low — 37% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $49.36 to $52.50. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 36.5% |
| From the all-time high | it is 100.0% below its all-time high | -100.0% |
| Nearest price level | it is trading 4.8% below a resistance level at $80.95 — a price it turned at twice since 2026-07-08, most recently on 2026-07-17. Since 2024-10-08 it has 12 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +4.8% |
| All-time low | its lowest closing price on record is $5.49 (set on 2025-04-09) | $5.49 |
| Above the all-time low | it is 1307.7% above its all-time low | +1,308% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 52nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $4.56 between its high and its low — about 5.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $4.56 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $75.58 and $99.77 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $75.58 – $87.67 – $99.77 |
| Typical daily range (% of price) | its price moves about 5.9% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.9% |
| Stretch from the 200-day average | it is trading 3.0 daily ranges above its 200-day average price (21.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.33× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 1.3% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.3% |
|---|---|---|
| Gap filled | a 2.7% gap down opened on 2026-09-08 has been "filled" 22 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 22 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 4 sessions in a row, a -8.57% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 4 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 19.1 percentage points (the stock lost 18.1% while the market gained 1.0%) | -19.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 12.3 percentage points (the stock lost 8.4% while the market gained 3.8%) | -12.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 19.6 percentage points (the stock gained 37.1% while the market gained 17.5%) | +19.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 226.7 percentage points (the stock gained 241.7% while the market gained 15.0%) | +226.7% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, its RSI momentum gauge is oversold (a beaten-down reading), outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 17% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 7.5% of the share price. | -17.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 7% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $72.18 — a volume-weighted average of daily closes over 183 sessions, not a true tick-by-tick VWAP. | +7.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 18% below the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is under water. That average is $94.07 — a volume-weighted average of daily closes over 43 sessions, not a true tick-by-tick VWAP. | -17.9% |
Price levels it has turned at before
ORKA last closed at $77.28 on 2026-10-08. Since 2024-10-08 it has turned at 12 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $80.95 | Resistance | 4.8% above the last close | turned there twice · 2026-07-08 to 2026-07-17 |
| $85.57 | Resistance | 10.7% above the last close | turned there twice · 2026-07-29 to 2026-08-31 |
| $98.03 | Resistance | 26.9% above the last close | turned there twice · 2026-06-30 to 2026-09-18 |
| $36.52 | Support | 52.7% below the last close | turned there twice · 2026-01-22 to 2026-02-25 |
| $32.07 | Support | 58.5% below the last close | turned there twice · 2025-12-10 to 2026-03-03 |
| $31.15 | Support | 59.7% below the last close | turned there three times · 2024-10-21 to 2026-03-12 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $98.29.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 10 trading days, since 2026-09-25.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Broke down to a new 20-day low · beating the market · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.15 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$155.00 range $117.00 – $200.00; median $155.50
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ORKA
- Consensus EPS estimate-$0.6183 next reporting period, as of 2026-10-04
- Estimate change, 30 days-$0.1181 from -$0.5002, on 2026-08-30, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical-stage company with no products approved for sale and no revenue generated from product sales.","History of significant operating losses and negative cash flows since inception.","Heavy dependence on the successful development and regulatory approval of its lead and co-lead pipeline programs."]
What changed in the latest 10-Q
AI-assisted comparison of ORKA's 10-Q filed 2026-05-13 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to Form 10-K filed March 12, 2026 for year ended December 31, 2025 (newer filing references 2025 10-K; older filing referenced 2024 10-K)
- Accumulated deficit of $221.0 million as of March 31, 2026
- Net losses of $31.8 million for three months ended March 31, 2026
- Net cash used of $23.6 million for operating activities for three months ended March 31, 2026
- Cash, cash equivalents, and marketable securities of $496.0 million as of March 31, 2026
- April 2026 public offering of 9,660,000 shares for gross proceeds of $700.4 million
- Addition of 'hidradenitis suppurativa (HS)' as an indication for ORKA-002
- Reference to 'FcRn' spelled out in full as 'neonatal Fc receptor' in ORKA-001 description
- Abbreviation 'TRMs' added for 'tissue-resident memory T cells' in Overview section
- Removed:
- References to 'reverse recapitalization and merger', 'Pre-Closing Financing', and 'PIPE Financings' removed from funding sources
- Reference to three and nine months ended September 30, 2025 net losses ($30.3 million and $75.9 million respectively)
- Reference to nine months ended September 30, 2025 net cash used ($65.6 million)
- Cash, cash equivalents, and marketable securities amount of $500.9 million as of September 30, 2025
- Reference to Phase 1 trial initiated in fourth quarter of 2024 and September 2025 interim results announcement (text truncated in older filing)
- Reworded:
- Quarterly period changed from 'September 30, 2025' to 'March 31, 2026'
- Subsidiary description changed from 'consolidated subsidiaries' (plural) to 'consolidated subsidiary' (singular)
- Change in ORKA-002 indications order: older lists 'PsO, psoriatic arthritis (PsA), and other conditions'; newer lists 'PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions'
- Parenthetical abbreviation format: older uses 'neonatal Fc receptor' without 'FcRn' abbreviation; newer uses '(FcRn)' abbreviation after phrase
- 'SQ injection' abbreviation added in newer filing for 'subcutaneous injection'
- Notes:
- Older filing MD&A section appears truncated at end (text cuts off mid-sentence: 'We initiated a Phase 1 trial...')
- Comparison reflects different quarterly reporting periods (Q3 2025 vs Q1 2026), which accounts for most numerical changes
- Some wording differences may reflect standard updates between quarterly periods rather than substantive policy changes
Risk Factors
- Added:
- Newer filing (2026-05-13) adds 'on the timeline we require' in discussion of raising capital
- Newer filing (2026-05-13) adds 'and economic' before 'regulatory uncertainty' in macroeconomic factors discussion
- Removed:
- Older filing (2025-11-12) stated 'We have not completed any clinical trials' in first bullet; newer filing (2026-05-13) changed to 'Our clinical trials remain ongoing'
- Older filing (2025-11-12) included bullet point: 'Our patents and our ability to protect our products may be impaired by changes to patent laws, and our patent protection could be reduced or eliminated for non-compliance with legal requirements'
- Older filing (2025-11-12) included bullet point: 'We may fail to identify or interpret relevant third-party patents'
- Older filing (2025-11-12) included bullet point: 'Patent terms may be inadequate to protect our competitive position of our programs'
- Older filing (2025-11-12) included bullet point: 'Third parties we rely on for the execution of nonclinical studies and clinical trials may fail to carry out their contractual duties'
- Older filing (2025-11-12) included bullet point: 'In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth'
- Older filing (2025-11-12) included bullet point: 'Significant disruptions of information technology systems or breaches of data security could adversely affect our business'
- Older filing (2025-11-12) included bullet point: 'Changes in and failures to comply with United States and foreign privacy and data protection laws, regulations and standards may adversely affect our business, operations and consolidated financial performance'
- Older filing (2025-11-12) included bullet point: 'We may become exposed to costly and damaging liability claims and our insurance may not cover all damages from such claims'
- Older filing (2025-11-12) included bullet point: 'We do not anticipate paying any dividends in the foreseeable future'
- Older filing (2025-11-12) included bullet point: 'Future sales of shares by existing stockholders could cause our stock price to decline' as separate item
- Reworded:
- Older filing (2025-11-12) titled section 'Summary of risk factors'; newer filing (2026-05-13) titled it 'Risk Factors Summary'
- Older filing (2025-11-12) referenced 'Item 1A of this Quarterly Report "Risk Factors"'; newer filing (2026-05-13) references 'Item 1A "Risk Factors" of this Quarterly Report'
- Older filing (2025-11-12) stated 'we may be harmed if we cannot'; newer filing (2026-05-13) states 'we may be harmed if we cannot' (same language in context of key personnel)
- Older filing (2025-11-12) stated 'we could exhaust our available financial resources sooner than we currently anticipate'; newer filing (2026-05-13) states 'we could exhaust our available financial resources sooner than we currently anticipate' (continuity note)
- Older filing (2025-11-12) listed 'Future sales of shares by existing stockholders could cause our stock price to decline' and 'Future sales and issuances of equity and debt could result in additional dilution' as separate items; newer filing (2026-05-13) consolidates order with 'Future sales and issuances of equity and debt' first
- Notes:
- The newer filing text provided appears truncated at the end of the full risk factors section, limiting complete comparison of detailed discussion paragraphs
- Bullet point consolidations in newer filing may reflect reordering rather than removal of substance
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 49 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 21 sells ($5M) — 5 selling insiders
- Last 90 days · read to 2026-10-040 buys · 49 sells ($21M) — 5 selling insiders
- Last 180 days · read to 2026-10-040 buys · 84 sells ($334M) — 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-01. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ORKA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ORKA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 20,529,616
- Reported value $1,953,789,697
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ORKA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ORKA had 7,623,327 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ORKA had 11.5% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.61 days to cover at the same settlement.
- Reported short interest (shares) 7,623,327
- Short interest (% of shares outstanding) 11.5%
- Prior settlement (shares) 7,793,678
- Reported change -2.19%
- Days to cover (reported) 11.61
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ORKA vs…
Frequently asked questions
What does ORUKA THERAPEUTICS INC (ORKA) do?
Oruka Therapeutics is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody therapeutics for chronic skin diseases and inflammatory and immunology indications. The company utilizes antibody engineering and half-life extension technology to target validated mechanisms, aiming to improve efficacy and dosing frequency for conditions such as psoriasis, hidradenitis suppurativa, and psoriatic arthritis.
What sector is ORUKA THERAPEUTICS INC (ORKA) in?
ORUKA THERAPEUTICS INC (ORKA) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are ORUKA THERAPEUTICS INC's (ORKA) competitors?
Notable peers of ORUKA THERAPEUTICS INC (ORKA) include AbbVie, Johnson & Johnson, Novartis, Eli Lilly and Amgen. This peer set is informational only — not financial advice.
Is ORUKA THERAPEUTICS INC (ORKA) overbought or oversold right now?
ORUKA THERAPEUTICS INC (ORKA) is currently in oversold territory (its 14-day RSI is 29, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ORKA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.